PBRM1-BD2-IN-8

Cat. No.:	HY-151538
CAS No.:	2819989-75-6
Molecular Formula:	$C_{15}H_{13}BrN_2O$
Molecular Weight:	317.18
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (315.28 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	3.1528 mL	15.7639 mL	31.5278 mL
	5 mM	0.6306 mL	3.1528 mL	6.3056 mL
	10 mM	0.3153 mL	1.5764 mL	3.1528 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (7.88 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PBRM1-BD2-IN-8 (compound 34) is a potent PBRM1 Bromodomain inhibitor (PBRM1-BD2 K_d=4.4 μM, PBRM1-BD2 IC_{50}=0.16 μM; PBRM1-BD5 K_d=25 μM). PBRM1-BD2-IN-8 shows anti-cancer activity[1].

IC_{50} & Target

IC_{50}: 0.16 μM (PBRM1-BD2)[1]

In Vitro

PBRM1-BD2-IN-8 (0-100 μM; 48 h) inhibits the growth of PBRM1-dependent prostate cancer cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	LNCaP cells
Concentration:	0-100 μM

Incubation Time:	48 hours
Result:	Inhibited the growth of LNCaP cells with IC_{50} value of about 9 μM.

REFERENCES

[1]. Shishodia S, et al. Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening. J Med Chem. 2022 Oct 13.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA